FDA warned www.dashpct.com over selling unapproved semaglutide drugs with unlawful labeling to U.S. consumers online.
What happened
FDA reviewed the website www.dashpct.com and found it offering semaglutide products marketed as Rybelsus 14mg and Rybelsus 7mg to U.S. consumers. FDA said there are no approved applications for those Novo Nordisk-made tablets offered by the site. FDA also said the prescription drugs' labeling lacks adequate directions for use by a layperson.
What FDA found
The website offers semaglutide products as new drugs without FDA-approved applications in effect.
FD&C Act §§ 301(d), 505(a) [21 U.S.C. §§ 331(d), 355(a)]By offering these prescription drugs to U.S. consumers, the website causes misbranded drugs to enter interstate commerce.
FD&C Act § 301(a) [21 U.S.C. § 331(a)]The prescription drugs' labeling lacks adequate directions for use by a layperson.
FD&C Act § 502(f)(1) [21 U.S.C. § 352(f)(1)]The drugs are prescription drugs that cannot be used safely without a licensed practitioner's supervision.
FD&C Act § 503(b)(1) [21 U.S.C. § 353(b)(1)]
What FDA wants
FDA tells www.dashpct.com to stop offering any unapproved and misbranded drugs for sale to U.S. consumers and to notify FDA in writing within 15 working days of steps taken, or explain delay and completion time.
Who should pay attention
- U.S. consumers who buy semaglutide online
- online pharmacies selling prescription drugs to U.S. patients
- companies distributing or sourcing semaglutide products
This is a summary. Read the original letter on fda.gov.